Literature DB >> 15183895

Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice.

Toni Peled1, Efrat Landau, Julie Mandel, Elina Glukhman, Noga R Goudsmid, Arnon Nagler, Eitan Fibach.   

Abstract

OBJECTIVE: We previously demonstrated that cellular copper is involved in the regulation of proliferation and differentiation of hematopoietic progenitor cells. Modulation of cellular copper was achieved by supplementing the culture with a copper chelator that reduces cell copper content, or copper salts, which elevate the level of cellular copper. In the present study, we evaluated the effect of short-term (3-week) treatment with the copper chelator tetraethylenepentamine (TEPA) on short- and long-term (up to 11 weeks) ex vivo expansion of hematopoietic progenitors, as well as on their SCID engraftment potential.
MATERIALS AND METHODS: Cord blood-derived purified CD34+ cells were grown in liquid medium supplemented with the cytokines stem cell factor, thrombopoietin, Flt3 ligand, and IL-6, and the chelator TEPA for the first 3 weeks and then for up to 11 weeks with cytokines alone. Control cultures were supplemented with cytokines alone for the entire culture duration. Cultured cells were characterized by immunophenotyping and cloning (CFUc). Transplantability was assayed by injection of repurified CD34+ cells into NOD/SCID mice.
RESULTS: In the short term, TEPA supported increased percentages of early progenitors over control cultures incubated with cytokines alone (CD34(+)CD38-, p=0.001 and CD34(+)Lin-, p=0.016). In the long term, TEPA pretreated cultures showed prolonged expansion of CD34+ cells (p=0.01) and CFUc (p=0.002) compared with that of untreated cultures. The SCID engraftment potential of CD34+ cells repurified from the TEPA-treated cultures was higher compared with that of the control, i.e., only cytokine-treated cultures (p=0.03).
CONCLUSION: TEPA enabled preferential proliferation of early progenitor cells with the phenotype CD34(+)CD38- and CD34(+)CD38- Lin- during the first weeks of culture, resulting in the observed increased long-term ex vivo expansion and engraftment capabilities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183895     DOI: 10.1016/j.exphem.2004.03.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  34 in total

Review 1.  Cord blood stem cells for hematopoietic transplantation.

Authors:  Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

Review 3.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

Review 4.  Ex vivo expansion of human hematopoietic stem and progenitor cells.

Authors:  Ann Dahlberg; Colleen Delaney; Irwin D Bernstein
Journal:  Blood       Date:  2011-03-23       Impact factor: 22.113

Review 5.  Optimizing autologous cell grafts to improve stem cell gene therapy.

Authors:  Nikoletta Psatha; Garyfalia Karponi; Evangelia Yannaki
Journal:  Exp Hematol       Date:  2016-04-19       Impact factor: 3.084

Review 6.  Proteins and small molecules for cellular regenerative medicine.

Authors:  Eric M Green; Richard T Lee
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

Review 7.  Novel chemical attempts at ex vivo hematopoietic stem cell expansion.

Authors:  Yu Zhang; Yingdai Gao
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

8.  Hematopoiesis and stem cell renewal in long-term bone marrow cultures containing catalase.

Authors:  Rashmi Gupta; Simon Karpatkin; Ross S Basch
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

9.  Negative selection by apoptosis enriches progenitors in naïve and expanded human umbilical cord blood grafts.

Authors:  K Mizrahi; S Ash; T Peled; I Yaniv; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

10.  Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.

Authors:  M de Lima; J McMannis; A Gee; K Komanduri; D Couriel; B S Andersson; C Hosing; I Khouri; R Jones; R Champlin; S Karandish; T Sadeghi; T Peled; F Grynspan; Y Daniely; A Nagler; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2008-01-21       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.